Compound comparison

muscle, sleep

3 RCT / 0 animal / 0 in vitro

injectable-sc

S2

Not approved

caution

—

Plasma half-life approximately 2 hours — longer than GHRP-6 (~30 min distribution phase) due to the structural features providing protease resistance

GHS-R1a (ghrelin receptor) agonist: Gq-protein coupled → PLC-IP3-Ca²⁺ pathway → GH granule exocytosis from pituitary somatotrophs.

muscle, sleep, weight-loss

0 RCT / 0 animal / 0 in vitro

injectable-sc

S2

Not approved

caution

—

The CIT Blend uses CJC-1295 WITHOUT DAC (also called Mod GRF 1-29) — the pulsatile form with ~30 min half-life

Mechanism diagram showing the compound's primary signaling pathway and downstream effects.

muscle, sleep

—

injectable-sc

S2

Not approved

caution

—

These four changes extend the plasma half-life from 4-7 minutes to approximately 30 minutes without meaningfully changing GHRH receptor binding affinity

Mechanism diagram showing the compound's primary signaling pathway and downstream effects.

muscle, sleep

0 RCT / 2 animal / 0 in vitro

injectable-sc

S2

Not approved

hard-stop

—

CJC-1295 is a synthetic GHRH(1-29) analog with four amino acid substitutions that resist DPP-IV degradation, extending the base half-life from 7 minutes to approximately 30 minu…

Mechanism diagram showing the compound's primary signaling pathway and downstream effects.